In 2024, the global Age-related Macular Degeneration (AMD) market is assumed at USD 11.79 billion, with an anticipated CAGR of 8.0 % during the forecast window. While that topline growth signals robust demand, the real value lies in how differentiated segments—by product type, disease subtype, delivery route, or end user—are evolving unevenly. A segmentation lens reveals which...